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Trastuzumab is the only HER2/neu-directed therapy to have received Food and Drug Administration approval for the treatment of
patients with metastatic breast cancer. The efficacy of trastuzumab depends on the HER2/neu status of the tumour and the patient’s
prior treatment, but even when patients are selected on the basis of HER2/neu gene amplification, the single-agent response rate
ranges from 12 to 30% and few patients respond to trastuzumab monotherapy. Here, we propose PTEN as a predictive biomarker
for trastuzumab efficacy. Human breast cancer SKBR3 and drug-resistant SKBR3/R cells were investigated. We also examined clinical
samples from patients who had been treated with trastuzumab and analysed the relationship between trastuzumab efficacy and
PTEN level. The PI3K/Akt signalling pathway was observed to be highly active in the drug-resistant cells, and their level of PTEN was
low. Delivery of antisense PTEN duplex siRNA significantly decreased the trastuzumab chemosensitivity of parental SKBR3 cells, and
marked activation of Akt signalling pathway was also recognised. Moreover, immunohistochemical investigation revealed that
trastuzumab treatment was remarkably successful in cells with elevated PTEN expression. Along with the immune-system-associated
cytotoxic mechanism, several mechanisms have been proposed for the effect of trastuzumab. PTEN activity might play an important
and major role in its HER2/PI3K/Akt-mediated antitumour effect, and could be a useful biomarker for predicting the efficacy of
trastuzumab in the treatment of breast cancer.
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PTEN (phosphatase and tensin homologue deleted on chromo-
some 10, also known as MMAC and TEP1) is a recently discovered
tumour-suppressor gene located on chromosome 10q23.3. PTEN
mutations have been implicated in variety of human cancers
including endometrial cancer (30–50%) (Risinger et al, 1997;
Tashiro et al, 1997), high-grade glioma (60–80%) (Louis and
Gusella, 1995) and prostate cancer (29%) (Cairns et al, 1997), and
homozygous deletion of the PTEN gene causes embryonic lethality
(Podsypanina et al, 1999). PTEN also antagonises phosphatidyl-
inositol 3 kinase (PI3K) function and negatively regulates Akt
activity. Restoration of PTEN expression in PTEN-null cells
inhibits Akt activity and tumour formation (Li and Sun, 1998;
Lu et al, 1999).
The HER2/neu oncogene, the second member of the epidermal
growth factor receptor family, encodes a transmembrane tyrosine-
kinase receptor. Overexpression of HER2/neu, which is seen in
approximately 30% of breast cancers, is associated with poor
overall survival (Yu and Hung, 2000) and in particular with
increased metastatic potential and resistance to chemotherapeutic
agents. Several reports have described the significance of PI3K and
the Akt pathway in HER2/neu signalling. PI3K and Akt have been
shown to play important roles in proliferation and cell survival and
induce the expression of many cytokines (Downward, 1998).
Recent studies have demonstrated that resistance to trastuzu-
mab treatment depends on the level of PTEN present (Crowder
et al, 2004; Nagata et al, 2004; Pandolfi, 2004), with Nagata et al
(2004) demonstrating that PTEN deficiency confers trastuzumab
resistance in HER2/neu-overexpressing breast cancer cells.
Here we present the use of PTEN for predicting the efficacy of
trastuzumab in drug-resistant and parental HER2/neu-overexpres-
sing breast cancer cells. We also investigate the expression of
PTEN in a clinical setting and discuss its role.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer SKBR3 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA) and
maintained in Dulbecco’s modified Eagle’s medium supplemented
with fetal bovine serum (10% vv
 1), penicillin (100IUml
 1) and
streptomycin (100mg/ml
 1) incubated in 5% CO2. Trastuzumab
resistance was developed by continuous exposure to trastuzumab
(4mgml
 1 for SKBR3/4R and 8mgml
 1 for SKBR3/8R) for 4
months, during which time the medium was replaced every 5 days
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sand cells were passaged when 50% confluence was reached.
Trastuzumab resistance was confirmed by dose–response studies
as described below.
Trastuzumab was purchased from Chugai Seiyaku (Tokyo,
Japan).
Western blot analysis
Cells (5–10 10
6) were washed twice with phosphate-buffered
saline (PBS), then lysed with a hypotonic HEPES buffer (250ml,
10mM, pH 7.6) containing KCl (50mM), phenylmethane sulphonyl
fluoride (0.1mM), aprotinin (0.5mlml
 1) and sodium orthovana-
date (0.1mM). After centrifugation, supernatants were adjusted to
contain equal concentrations of protein, diluted with one volume
of 5  SDS sample buffer and heated for 5min at 951C. Samples
(30mg protein) were run on a 4–20% SDS–PAGE gel and
electroblotted onto polyvinylidene fluoride membrane. Blots were
blocked overnight in blocking solution (5% nonfat milk powder,
0.1% Tween 20 in PBS) at 41C. Afterwards, the blots were exposed
to antibodies against HER2, PI3K, Akt, PTEN (Santa Cruz, CA,
USA), p-PI3K or p-Akt (Cell Signalling) at 1000-fold dilution in
blocking solution (1h, room temperature). After extensive washing
with blocking solution, blots were exposed to the appropriate
secondary antibody at 10000-fold dilution in blocking solution.
After extensive washing, blots were examined using an enhanced
chemiluminescence detection method (ECL kit, Amersham Phar-
macia Biotech, Chandler, AZ, USA).
Determination of cytotoxicity by MTT
(3-[4,5-dimethylthyazol-2-yl]-2,5-diphenyl tetrazolium
bromide) assay
Cells were seeded at a concentration of 3 10
3 cells per well in flat-
bottomed 96-well microplates. After 24h, the cells were cultivated
with trastuzumab for 120h or paclitaxel for 12h, or left untreated,
then their viability was determined using Promega’s CellTiter 96
s
Aqueous One Solution Cell Proliferation Assay (Promega Corp.,
Madison, WI, USA).
Delivery of PTEN duplex siRNA in vitro
Duplex siRNA against PTEN (AF143314 4688 E06: 50-AUGCCAA
CAACAAGCUUCUUACAAUGCC-30) and control duplex siRNA
(AF143314 4688 E07: 50-AUGUACCAACCGAAUCUUACAUGCC-30)
(Life Technologies, Rockville, MD, USA) were delivered in drug-
sensitive parental SKBR3 cells. Cells were plated in 100mm dishes
at 30% confluence and transfected with duplex siRNA (25nM)
using Oligofectamine (Life Technologies, Rockville, MD, USA) 48h
postplating. Cells were replated for individual assay 96h postplat-
ing. PTEN expression was determined 120h postplating and
growth inhibition assay was performed after 72h postplating
followed by incubation with chemotherapeutic agents.
Evaluation of HER2/neu status
HER2/neu status was determined based on gene amplification and/
or immunohistochemical evaluation. HER2/neu gene amplification
of the patients’ samples was determined by fluorescence in situ
hybridisation (FISH) using the PathVysion FISH assay (Vysis, IL,
USA). Immunohistochemically, HER2/neu status was determined
by Herceptest (DAKO, Tokyo, Japan).
Immunohistochemical investigation of PTEN
Clinical samples were used for immunohistochemical investigation
with PTEN. Each sample was obtained from a surgical specimen of
a patient who had received trastuzumab treatment in combination
with paclitaxel in our department between 2001 and October 2005.
For immunohistochemistry, paraffin sections were stained after
microwave treatment by an intact method. Antibody against PTEN
(Santa Cruz, CA, USA) was exposed overnight at 41C followed by
treatment with the LSAB2 kit (DAKO Carpinteria, CA, USA)
according to the manufacturer’s instructions. The PTEN expres-
sion level was scored semiquantitatively based on staining
intensity and distribution using the immunoreactive score (IRS)
as described elsewhere (Friedrichs et al, 1993; Chui et al, 1996);
briefly, IRS¼SI (staining intensity) PP (percentage of positive
cells). Staining intensity is assigned as 0, negative; 1, weak; 2,
moderate; 3, strong. Percentage of positive cells is defined as 0,
o1%; 1, 1–10%; 2, 11–50%; 3, 51–80%; and 4, 480% positive
cells. In all, 10 visual fields from different areas of each tumor were
used for the IRS evaluation. Negative control slides without
primary antibody were included for each staining. Normal breast
epithelium or vascular endothelium known to express normal
PTEN was used as positive control. Based on the IRS score,
staining intensity was graded   (IRS 0–3), 1þ (IRS 4–6), 2þ
(IRS 7-9) or 3þ (IRS 10–12).
Statistical analysis
Levels of statistical significance were evaluated using data from at
least three independent experiments by using the two-tailed
Student’s t test, Fisher’s test and ANOVA. Po0.05 was considered
to be statistically significant. All data were analysed using StatView
for Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS
Growth inhibition of trastuzumab and paclitaxel in
parental and drug-resistant cells
The HER2/neu-overexpressing SKBR3 cells were treated with serial
dilutions of trastuzumab and paclitaxel. The cells’ survival at
various drug concentrations are shown in Figure 1. In the drug-
resistant cells, mean cell viability was 79.6% (SKBR3/4R) and
128.6% (SKBR3/8R) at 2mgml
 1 trastuzumab, which is markedly
higher than the wild-type (SKBR3/WT) parental cells. Mean cell
viabilities (IC50) in parental and resistant SKBR3/4R cells were 8.25
and 23.79mM trastuzumab, respectively; the difference was
statistically significant (Figure 2). However, the response of
drug-resistant and parental cells to paclitaxel treatment did not
differ significantly.
Western blotting analysis of HER2/neu expression and
downstream signal proteins
Western blot was performed to detect expression of the down-
stream cascade pathway of HER2/neu2 in both resistant and
parental cells. Expression of HER2/neu, PI3K, phosphorylated
PI3K and nonphosphorylated Akt were the same in both cell types
(Figure 3a). However, expression of phosphorylated Akt was
significantly higher in the drug-resistant cell lines. Conversely,
PTEN expression was decreased in the drug-resistant cells and this
downregulation was more pronounced in the more resistant cells.
Owing to the downregulation of PTEN, expression of phosphory-
lated Akt was increased and signal transduction of the Akt-
mediated pathway was activated (Figure 3b).
PTEN deficiency and trastuzumab sensitivity in parental
cells
To elucidate the effect of PTEN on trastuzumab’s efficacy,
SKBR3/WT, 4R and 8R cells were transfected with PTEN antisense
oligonucleotides, which effectively reduced endogenous
PTEN activity and trastuzumab efficacy
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sPTEN expression compared with the cells transfected with
control mismatched (MIS) oligonucleotides (Figure 4). To
investigate whether PTEN activation contributes to trastuzumab’s
antiproliferation function, we compared cell growth between
MIS control and PTEN antisense-delivered SKBR/WT cells
after trastuzumab treatment. PTEN antisense-delivered
SKBR3/WT cells, which had reduced PTEN expression, showed
significantly less growth inhibition with trastuzumab than MIS
control-delivered cells with a normal level of PTEN expression
(Figure 5).
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Figure 1 (A) Growth inhibition assays revealed that chemosensitivity to
trastuzumab was decreased in drug-resistant SKBR3/4R and /8R cells (120h
incubation with trastuzumab after 24h incubation with medium). (B)
Chemosensitivity of paclitaxel was not significantly different in drug-resistant
and parental SKBR3 cells (12h incubation with paclitaxel after 24h
incubation with medium).
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Figure 2 The IC50 value of trastuzumab in drug-resistant SKBR3/4R cells
was statistically significantly higher than in parental cells.
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Figure 3 (A) Western blotting analysis revealed that the level of
expression of the ErbB2/PI3K/Akt signal transduction pathway is the same
in trastuzumab-resistant and parental cells. (B) Phosphorylated Akt activity
was increased in drug-resistant SKBR3/R cells; PTEN expression was
decreased in these cells.
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Figure 4 Western blotting analysis of antisense-delivered SKBR3/WT
cells showed that expression of PTEN was inhibited by duplex antisense-
siRNA delivery.
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Figure 5 The growth inhibition curve of duplex antisense-siRNA-
delivered SKBR3/WT cells shows decreased trastuzumab sensitivity (120h
incubation of trastuzumab 72h postplating).
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sWestern blotting analysis of HER2/neu expression and
downstream signal proteins in PTEN-deficient cells
Western blot was used to detect the expression of the downstream
cascade pathway of HER2/neu in PTEN antisense-delivered cells.
Expression of nonphosphorylated Akt was the same in all cells, but
expression of phosphorylated Akt was significantly higher in
antisense-delivered SKBR3/WT cells than in drug-resistant cells
(Figure 6).
Growth inhibition effect of paclitaxel in PTEN-deficient
cells
The growth-inhibition effect of paclitaxel was analysed in PTEN-
deficient cells. No significant difference was observed between
PTEN antisense-delivered cells and MIS control-delivered cells
(Figure 7).
Immunohistochemical analysis of PTEN in clinical
specimens
To explore the clinical significance of PTEN status in predicting
response to trastuzumab-based therapy, we evaluated PTEN
expression in 17 HER2/neu-overexpressing primary breast carci-
nomas from patients who subsequently developed metastatic
breast cancer and received trastuzumab plus paclitaxel therapy
after preliminary evaluation, and in 20 other randomly selected
breast cancer patients. Immunohistochemical staining revealed
that PTEN expression in these tumours was heterogeneous. Thus,
PTEN expression levels were semiquantified using IRS, calculated
by multiplying the percentage of PTEN-positive cells (scored 0–4)
by the PTEN staining intensity (scored 1–3) (Chui et al, 1996).
Immunoreactive scores range from 0 to 12, representing the range
of PTEN staining from an undetectable level in PTEN-deficient
tumours to full expression in normal individuals (Figure 8). We
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Figure 6 Western blotting analysis of antisense-delivered SKBR3/WT
cells showed that expression of phosphorylated Akt was increased. This
suggests that Akt activity is partly due to the level of PTEN in ErbB2-
overexpressing SKBR3 cells.
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Figure 7 The growth inhibition rate of paclitaxel in antisense-delivered
SKBR3/WT cells. No significant difference was observed for the growth
inhibition effect of paclitaxel between antisense- and control oligonucleo-
tide-delivered cells (12h incubation of paclitaxel 72h postplating).
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Figure 8 PTEN expression pattern in human breast tumours. ErbB2-overexpressing primary breast carcinomas from 17 patients who subsequently
received trastuzumab plus pacliataxel were analysed. PTEN expression of these tumours was examined by IHC and semiquantified using immunoreactive
scores. Representative tumour PTEN stainings (IRS 3þ,2þ,1þ, and  ).
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sobserved weak PTEN expression (  and 1þ: IRSo7) in 40.0–
49.1% of the tumours examined (eight out of 17 of the patients
who received trastuzumab and paclitaxel, and eight out of 20 from
the preliminary study), which is consistent with previous reports
that B50% of breast cancers are PTEN deficient (Perren et al,
1999; Depowski et al, 2001). Of the 17 patients who received
trastuzumab plus paclitaxel, those who had PTEN-deficient
tumours (  and 1þ: IRSo7) had significantly lower complete
and partial response rates to trastuzumab therapy than those with
PTEN-positive tumors (2þ and 3þ or IRSX7; 12.50 vs 88.89%,
P¼0.00337) (Figure 9).
DISCUSSION
Several studies using either primary tumour tissue or established
tumour cell lines have demonstrated a high frequency of PTEN
mutation/deletion in various human cancers including brain,
bladder, breast, prostate and endometrial cancers (Louis and
Gusella, 1995; Cairns et al, 1997; Li et al, 1997; Risinger et al, 1997;
Tashiro et al, 1997; Teng et al, 1997; Podsypanina et al, 1999;
Mutter et al, 2000). PTEN has been found to be one of the most
common targets of mutation in human cancer, with a mutation
frequency approaching that of p53 (Bose et al, 1998). Human
breast cancer is associated with a loss of heterozygosity or
mutation of the PTEN gene, and decreased PTEN expression is
associated with invasive breast cancer and poor prognosis (Singh
et al, 1998; Garcia et al, 1999). The principal activity of PTEN is to
dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3),
produced by PI3K and a major activator of the cell survival kinase
Akt. Thus, negative regulation of the PI3K pathway by PTEN is
critical, and loss of PTEN function creates an environment
conducive to tumorigenesis (Feilotter et al, 1999; Perren et al,
1999; Torres and Pulido, 2001). Currently, patients with metastatic
breast cancer are selected for trastuzumab-based therapy if the
primary tumour overexpresses the HER2/neu protein, or if FISH
provides evidence of HER2/neu gene amplification (Di Cristofano
et al, 1998). While trastuzumab therapy is not a cure for
disseminated disease in HER2/neu amplification cases, major
tumour regressions are often seen, particularly when the
trastuzumab is given in combination with other chemotherapeutic
agents. However, in spite of patient selection on the basis of HER2/
neu FISH or protein overexpression, less than 30% of patients
respond to trastuzumab monotherapy. Taking these observations
into account, HER2/neu gene amplification is a necessary
biomarker but not sufficient to predict the efficacy of trastuzumab.
It is probable that trastuzumab efficacy is also controlled by other
biomarkers associated with the downstream pathway of HER2/neu.
Some recent reports have demonstrated that PTEN activation
contributes to tumour inhibition by trastuzumab, and loss of
PTEN predicts trastuzumab resistance in vitro, in vivo and in the
clinical setting (Crowder et al, 2004; Nagata et al, 2004; Pandolfi,
2004). According to Nagata et al (2004), activation of PTEN in
HER2/neu-amplified breast cancer could contribute to the efficacy
of trastuzumab; it was also demonstrated that efficacy of
trastuzumab in clinical samples of HER2/neu-amplified breast
cancer is significantly associated with PTEN expression.
In this in vitro study, we investigated the relationship between
trastuzumab’s efficacy and PTEN status with a drug-resistant cell
model established by continuous exposure to trastuzumab. Our
method for the establishment of trastuzumab-resistant HER2/neu-
overexpressing breast cancer cells is similar to that of Nahta et al
(2004) and could provide a model for the investigation of the
molecular mechanisms of trastuzumab resistance. As in previous
reports (Crowder et al, 2004; Nagata et al, 2004; Pandolfi, 2004),
our study revealed a remarkable difference in PTEN activity
between drug-sensitive and -resistant cells. Selective inhibition of
PTEN, which is strongly associated with induction of Akt activity,
resulted in markedly decreased trastuzumab sensitivity. Further-
more, in the clinical samples from patients with HER2/neu-
overexpressing breast cancer treated with trastuzumab, PTEN
expression was strongly associated with trastuzumab efficacy.
Therefore, based on this study and previous reports, trastuzumab
efficacy is partly dependent on the PTEN status and degree of Akt
and associated signal transduction activities in HER2/neu-over-
expressing breast cancer.
Although we have not described the studies here, we have also
investigated the effects of selective inhibition of other signal
transduction pathways and transcription factors, including the
Ras/Raf/MAPK pathway, JNK-medicated pathway and bcl2 apop-
totic proteins, in trastuzumab-sensitive and -resistant SKBR3 cells.
Little effect on trastuzumab efficacy was observed.
Other reports have discussed other predictive markers of
trastuzumab efficacy (Albanell and Baselga 2001; Lu et al, 2001,
2004; Menendez et al, 2005; Vogel et al, 2005), including insulin-
like growth factor-1 receptor (IGF-1R), a widely expressed protein
tyrosine kinase with an important role in the suppression of
apoptosis and stimulation of proliferation. However, these studies
have not yet been expanded to the clinical setting (Lu et al, 2001).
Our findings are strongly supported by clinical data and previous
reports (Crowder et al, 2004; Nagata et al, 2004; Pandolfi, 2004)
that PTEN-deficient tumours did not respond to trastuzumab.
Therefore, PTEN, which is strongly associated with the PI3K/Akt
signal transduction pathway, could predict the efficacy of
trastuzumab in patients with excessive HER2/neu expression.
Owing to the small cohort used in our study, further large-scale
clinical investigations, including both histopathological and
genetic aspects, should be carried out.
Several new molecular-target chemotherapeutic agents have been
developed in recent years. Of these, selective inhibitors of Akt and
mTOR have been examined in preclinical or Phase 1 clinical trials
(Carraway and Hidalgo, 2004; Meuillet et al, 2004). According to
the results of our study, the PTEN and Akt downstream pathway is
critical for the efficacy of trastuzumab and these new agents
targeted to the HER2/neu-mediated transduction pathway might
give hope in overcoming trastuzumab resistance.
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Figure 9 Immunohistochemical investigation of PTEN expression from
patients with erbB2-overexpressing breast cancer treated with trastuzu-
mab. We analysed 17 breast cancer tissue samples by immunohisto
chemistry. In those cases with increased PTEN expression (3þ,2þ), the
efficacy of trastuzumab-containing chemotherapy was remarkable and the
response rate statistically significant (statistical analysis was performed with
Fisher’s test).
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